Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 5/20 | 0.48 |
| ▸ | IL2 | P60568 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19476080 | 0.86 | CYP1A2 (0.52) | L3MBTL1TDP1MAPTLMNANPSR1 | |
| SCHEMBL19476093 | 0.86 | KMT2A (0.59) | MAPTHDAC3HDAC1LMNASMN1; SMN2 | |
| SCHEMBL19476167 | 0.82 | NPC1 (0.60) | L3MBTL1TDP1LMNASMN1; SMN2ATM | |
| SCHEMBL19476077 | 0.81 | KDM4E (0.54) | L3MBTL1TDP1MAPTHDAC3HDAC1 | |
| SCHEMBL914735 | 0.76 | SRD5A2 (0.64) | MAPTLMNAIDO1TDO2MAPK1 | |
| SCHEMBL19476141 | 0.75 | TP53 (0.65) | L3MBTL1TDP1MAPTHDAC3HDAC1 | |
| SCHEMBL19476395 | 0.75 | RAB9A (0.56) | L3MBTL1TDP1MAPTATMRAB9A | |
| SCHEMBL19476090 | 0.74 | KDM4E (0.71) | L3MBTL1MAPTNPSR1TSHRRAB9A | |
| SCHEMBL19476394 | 0.74 | MEN1 (0.58) | MAPTHDAC3HDAC1NPSR1RAB9A | |
| SCHEMBL12190092 | 0.73 | L3MBTL1 (0.71) | L3MBTL1TDP1MAPTLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759765-B2 | Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute | CE PHARM CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| US-20190127337-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | CE PHARM CO., LTD. (CN) | 2019-05-02 | — | — | US | disclosed |
| WO-2017177979-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | 中国科学院上海有机化学研究所 | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127337-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | AOC1, AOC2, AOC3 | L3MBTL1 4182/4885TDP1 4832/4885MAPT 4463/4885 |
| US-10759765-B2 | Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute | AOC1, AOC2, AOC3 | L3MBTL1 4182/4885TDP1 4832/4885MAPT 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.